ポスター：細胞治療薬のGxP環境下における次世代シーケンス（NGS）を用いた重要品質特性（CQA）の同定
March 11, 2024
In the race to make life-changing cell therapies more accessible, maintaining in-process critical quality attributes (CQAs) remains necessary to ensure the delivery of safe and effective treatment. CQAs such as Identity, Potency, and Safety, can be efficiently monitored by implementing Next-Generation Sequencing (NGS) at various stages of development and manufacturing.
Download this poster to learn how Genedata Selector® workflows eliminate the need to implement multiple different assays to determine CQAs and discover:
- How our technology-agnostic platform supports all types of NGS-based assays throughout the CT vector development process
- How the platform's wizard-based Playbooks simplify and automate NGS-based assays for CT development
- How the platform enables data traceability for all analyses and report generation for internal and external audits
- How the platform's interactive tools provide unique insights into cell properties and product efficacy
